Molecular Profile | RET C634R RET Y806C |
Therapy | Vandetanib |
Indication/Tumor Type | Advanced Solid Tumor |
Response Type | resistant |
Create By | cstatz |
Update By | cstatz |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References | RET C634R RET Y806C | Advanced Solid Tumor | resistant | Vandetanib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed human cells co-expressing RET C634R and RET Y806C were resistant to treatment with Caprelsa (vandetanib) in culture (PMID: 19029224). | 19029224 |
---|
PubMed Id | Reference Title | Details |
---|---|---|
(19029224) | Identification of tyrosine 806 as a molecular determinant of RET kinase sensitivity to ZD6474. | Full reference... |